Kyntra Bio, Inc. (KYNB)
NASDAQ: KYNB · Real-Time Price · USD
6.70
-0.20 (-2.90%)
Sep 29, 2026, 1:28 PM EDT - Market open

Kyntra Bio Stock Forecast

Stock Price Forecast

According to 4 analysts polled by S&P Global, Kyntra Bio stock has a consensus rating of "Buy" and an average price target of $39.67. The average 1-year stock price forecast is 492.09% higher than the current stock price, while the lowest is $35 (+422.39%) and the highest is $43 (+541.79%).

Price Target: $39.67 (+492.09%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$35$39.67$41$43
Change+422.39%+492.09%+511.94%+541.79%

Analyst Ratings

The average analyst rating for Kyntra Bio stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingFeb '26Mar '26May '26Jul '26Aug '26Sep '26
Strong Buy111222
Buy000000
Hold111111
Sell000000
Strong Sell000000
Total222333

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Lake Street
Lake Street
Buy
Initiates
$41
BuyInitiates$41+511.94%Sep 17, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$43
BuyReiterates$43+541.79%Sep 1, 2026
William Blair
William Blair
Hold
Reiterates
n/a
HoldReiteratesn/an/aSep 1, 2026
Oppenheimer
Oppenheimer
Buy
Maintains
$35
BuyMaintains$35+422.39%Aug 14, 2026
Rodman & Renshaw
Rodman & Renshaw
Buy
Initiates
$30
BuyInitiates$30+347.76%Jun 9, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
6.71M
from 6.44M
Increased by 4.23%
Revenue Next Year
7.66M
from 6.71M
Increased by 14.15%
EPS This Year
-12.41
from 45.37
EPS Next Year
-14.23
from -12.41
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
235.31M140.73M46.80M29.62M6.44M6.71M
Revenue Growth
33.46%-40.19%-66.74%-36.71%-78.26%4.23%
Operating Income
-348.53M-301.03M-334.75M-130.96M-45.34M-57.49M
Net Income
-290.02M-293.65M-284.23M-47.58M183.45M-39.29M
EPS
----45.37-12.41
Free Cash Flow
------53.16M
No. Analysts
-----4
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High8.9M
Avg6.7M
Low4.8M

Revenue Growth

Revenue Growth202620272028
High
38.2%
Avg
4.2%
Low
-25.5%

EPS Forecast

EPS202620272028
High-12.41
Avg-12.41
Low-12.41

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-